Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-hepatic fibrosis pharmaceutical composition and application thereof

A technology of anti-hepatic fibrosis and composition, which is applied in the field of medicine, can solve the problems of complex molecular mechanisms and difficult drug effects, and achieve the effects of enhancing immune function, regulating liver blood microcirculation, and preventing and controlling high blood pressure

Pending Publication Date: 2019-12-06
成秋宸
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention overcomes the technical problem in the prior art that due to the complex molecular mechanism of liver fibrosis involving multiple molecular pathways, it is difficult for a single-target drug to have good efficacy, and provides a natural product pharmaceutical composition for the treatment of liver fibrosis The application in liver fibrosis can improve the ability of liver cells to resist oxidation, anti-inflammation and anti-fibrosis through multi-target effects on liver fibrosis pathway, and delay or reverse the process of liver fibrosis, so as to achieve the purpose of treating liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-hepatic fibrosis pharmaceutical composition and application thereof
  • Anti-hepatic fibrosis pharmaceutical composition and application thereof
  • Anti-hepatic fibrosis pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] This embodiment provides an anti-hepatic fibrosis pharmaceutical composition, which is a preparation prepared from the following raw materials by weight: 1 part of Chitosan, 2 parts of Genistein, 3 parts of EGCG, and 20 parts of Taurine.

[0033] Its preparation method comprises the following steps:

[0034] S1: Weigh the raw material by weight;

[0035] S2: Take the raw material drug as the active ingredient, add the commonly used pharmaceutical excipients or auxiliary ingredients to make various dosage forms suitable for clinical application.

[0036] This embodiment also provides the application of the above-mentioned pharmaceutical preparation containing the anti-hepatic fibrosis pharmaceutical composition as an active ingredient in the preparation of an anti-hepatic fibrosis drug.

Embodiment 2

[0038] This example provides an anti-hepatic fibrosis pharmaceutical composition, which is a preparation prepared from the following raw materials in parts by weight: 3 parts of Chitosan, 6 parts of Genistein, 9 parts of EGCG, and 60 parts of Taurine.

[0039] Its preparation method comprises the following steps:

[0040] S1: Weigh the raw material by weight;

[0041] S2: Take the raw material drug as the active ingredient, add the commonly used pharmaceutical excipients or auxiliary ingredients to make various dosage forms suitable for clinical application.

[0042] This embodiment also provides the application of the above-mentioned pharmaceutical preparation containing the anti-hepatic fibrosis pharmaceutical composition as an active ingredient in the preparation of an anti-hepatic fibrosis drug.

Embodiment 3

[0044] This embodiment provides an anti-hepatic fibrosis pharmaceutical composition, which is a preparation prepared from the following raw materials in parts by weight: 5 parts of Chitosan, 10 parts of Genistein, 15 parts of EGCG, and 100 parts of Taurine.

[0045] Its preparation method comprises the following steps:

[0046] S1: Weigh the raw material by weight;

[0047] S2: Take the raw material drug as the active ingredient, add the commonly used pharmaceutical excipients or auxiliary ingredients to make various dosage forms suitable for clinical application.

[0048] This embodiment also provides the application of the above-mentioned pharmaceutical preparation containing the anti-hepatic fibrosis pharmaceutical composition as an active ingredient in the preparation of an anti-hepatic fibrosis drug.

[0049] The present invention demonstrates that the pharmaceutical composition of the present invention (hereinafter referred to as CGET drug) has the effect of treating li...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-hepatic fibrosis pharmaceutical composition and application thereof. The anti-hepatic fibrosis pharmaceutical composition is a preparation prepared from the following raw material drugs in parts by weight: 1-5 parts of Chitosan, 2-10 parts of Genistein, 3-15 parts of EGCG, and 20-100 parts of Taurine. The anti-hepatic fibrosis pharmaceutical composition is applied to preparation of an anti-hepatic fibrosis drug; and through multi-target-point action on a hepatic fibrosis path, the anti-hepatic fibrosis pharmaceutical composition has the characteristics that theability to resist oxidation, inflammation and fibrosis of liver cells is improved, the hepatic fibrosis progress of model animals is delayed or reversed, obvious liver toxicity is avoided, the qualityis stable and controllable, and sources are wide, and the anti-hepatic fibrosis pharmaceutical composition has good application prospects in resisting of hepatic fibrosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for resisting liver fibrosis and its application. Background technique [0002] More than 10% of the world's people suffer from chronic liver disease, among which there are more than 100 million patients with liver fibrosis, and more than 1 million patients die each year due to liver fibrosis. Hepatic fibrosis is caused by chronic viral hepatitis, cholestasis, drug-induced liver injury, parasitic infection, chronic alcoholic liver disease, and autoimmune hepatitis. It is a compensatory response in the repair process of inflammatory damage. It is the only way to progress to liver cirrhosis. Liver fibrosis is considered to be a reversible stage, so it becomes the best period for clinical drug intervention to reverse liver fibrosis, delay, prevent, or even reverse liver fibrosis, which is helpful for improving liver function of patients, delaying the f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/722A61P1/16A61K31/185A61K31/352A61K31/353
CPCA61K31/722A61K31/353A61K31/185A61K31/352A61P1/16A61K2300/00
Inventor 成秋宸覃雯卓朗
Owner 成秋宸
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com